Cited 35 times in
Design and Rationale for a Phase III, Randomized, Placebo-controlled Trial of Durvalumab With or Without Tremelimumab After Concurrent Chemoradiotherapy for Patients With Limited-stage Small-cell Lung Cancer: The ADRIATIC Study
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.